01—Abstract
Summary
Summary of the 8-K filed September 16, 2024. Cited figures are marked; the original filing is the authoritative source.
Centene Corporation (CNC) has filed an 8-K to disclose information related to upcoming investor meetings and its financial guidance.
The company will be meeting with investors on September 17, 2024, and presenting at the Bank of America 2024 Global Healthcare Conference on September 18, 2024. During these engagements, Centene expects to reaffirm its full-year 2024 adjusted diluted earnings per share (EPS) guidance of greater than $6.80a. The filing also emphasizes Centene's use of non-GAAP financial measures, such as adjusted diluted EPS, to provide a clearer view of ongoing operational performance and to facilitate consistent period-to-period comparisons.
The company believes these measures, which exclude items like amortization of acquired intangible assets and acquisition-related expenses, offer meaningful insights into its core business. However, Centene cautions investors that these non-GAAP measures may differ from those used by other companies and should be reviewed alongside GAAP financial information. A reconciliation of the 2024 adjusted diluted EPS guidance to the comparable GAAP measure is not provided due to the difficulty in predicting certain timing and amounts of non-recurring items.
02—Key points
Key Highlights
- Centene Corp. reaffirms its full-year 2024 adjusted diluted EPS guidance of greater than $6.80.
- The company is participating in investor meetings on September 17, 2024, and presenting at the Bank of America 2024 Global Healthcare Conference on September 18, 2024.
- Centene utilizes non-GAAP financial measures, such as adjusted diluted EPS, to provide insights into ongoing operational performance.
- These non-GAAP measures exclude items like amortization of acquired intangible assets and acquisition/divestiture related expenses.
- The company believes these non-GAAP metrics allow for a more consistent assessment of performance across periods.
- Investors are encouraged to review GAAP financial statements alongside non-GAAP measures, as definitions may vary across companies.
- A reconciliation of the 2024 adjusted EPS guidance to the most comparable GAAP measure is not currently available due to the unpredictable nature of certain items.
03—Questions
Frequently Asked Questions
What is the key financial guidance Centene is reaffirming?
Centene Corporation is reaffirming its full-year 2024 adjusted diluted earnings per share (EPS) guidance of greater than $6.80.
When and where will Centene be presenting?
Centene will be meeting with investors on September 17, 2024, and presenting at the Bank of America 2024 Global Healthcare Conference in London on September 18, 2024, at 5:50 am EDT / 10:50 am BST.
Why does Centene use non-GAAP financial measures like adjusted diluted EPS?
Centene uses non-GAAP measures to provide investors with a more accurate assessment of the ongoing nature of its operations and to measure performance more consistently across periods. These measures exclude certain items like amortization of acquired intangible assets and acquisition/divestiture related expenses, which the company believes helps investors better understand core business performance.
Can investors rely solely on the non-GAAP financial measures provided?
No, investors should review Centene's consolidated financial statements and publicly filed reports in their entirety. The company advises that its non-GAAP measures may differ from similar measures used by other companies and should not be considered in isolation or as a substitute for GAAP financial information.
04—Continue